A new positron emission tomography radiotracer enables imaging of the human glutamate receptor AMPA-R, a fundamental component of neurotransmission involved in neuropsychiatric disorders.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Miyazaki, T. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0723-9 (2020).
Malinow, R. & Malenka, R. C. Annu. Rev. Neurosci. 25, 103–126 (2002).
Pilowsky, L. S. et al. Mol. Psychiatry 11, 118–119 (2006).
Bressan, R. A. et al. Biol. Psychiatry 58, 41–46 (2005).
Ahmed, A. H., Ptak, C. P. & Oswald, R. E. Biochemistry 49, 2843–2850 (2010).
Mathern, G. W. et al. J. Neuropathol. Exp. Neurol. 57, 615–634 (1998).
Mathern, G. W. et al. Brain 120, 1937–1959 (1997).
Finnema, S. J. et al. Sci. Transl. Med. 8, 348ra96 (2016).
Lam, J. et al. Ann. Neurol. 85, 218–228 (2019).
DeLorenzo, C. et al. Biol. Psychiatry 77, 266–275 (2015).
Martin-Facklam, M. et al. Neuropsychopharmacology 38, 504–512 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.H.K. is supported by funds from the US Department of Veterans Affairs via its support of the National Center for PTSD, by the National Institute on Alcohol Abuse and Alcoholism via its support of the Center for the Translational Neuroscience of Alcoholism (P50 AA021818), and the National Center for Advancing Translational Science (NCATS) via its support for CTSA Grant Number UL1 TR001863. J.H.K. is a co-sponsor of a patent for the intranasal administration of ketamine for the treatment of depression and for the treatment of suicide risk that was licensed by Janssen Pharmaceuticals; has a patent related to the use of riluzole to treat anxiety disorders that was licensed by Biohaven Pharmaceuticals; has stock or stock options in Biohaven Pharmaceuticals, Blackthorn Therapeutics, Luc Therapeutics, Cadent Pharmaceuticals, Terran Biosciences, Spring Healthcare, and Sage Pharmaceuticals; serves on the Board of Directors of Inheris Pharmaceuticals; leads two studies in which pharmaceutical companies (Cerevel Pharmaceuticals and Novartis) have provided access to drugs without charge; has received, over the past 3 years, over US$5,000 in compensation for consulting to Sunovion, Takeda, Novartis, and Janssen Pharmaceuticals; and receives over US$5,000 in income from the Society of Biological Psychiatry in compensation for serving as editor of the journal Biological Psychiatry.
Rights and permissions
About this article
Cite this article
Krystal, J.H. Imaging the glutamate synapse. Nat Med 26, 165–167 (2020). https://doi.org/10.1038/s41591-020-0760-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0760-4
